| 04/21/2026 3:30 PM | MoonLake Immunotherapeutics (1821586) Filer | Form DEF 14A | |
| 04/21/2026 3:31 PM | MoonLake Immunotherapeutics (1821586) Filer | Form DEFA14A | |
| 04/21/2026 3:31 PM | MoonLake Immunotherapeutics (1821586) Filer | Form ARS | |
| 04/16/2026 3:10 PM | Bodenstedt Matthias (1920545) Reporting MoonLake Immunotherapeutics (1821586) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/14/2026 4:55 PM | MoonLake Immunotherapeutics (1821586) Issuer Santos da Silva Jorge (1920509) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/10/2026 5:06 PM | Bodenstedt Matthias (1920545) Reporting MoonLake Immunotherapeutics (1821586) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/10/2026 8:56 AM | MoonLake Immunotherapeutics (1821586) Subject Santos da Silva Jorge (1920509) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/09/2026 3:01 PM | Bodenstedt Matthias (1920545) Reporting MoonLake Immunotherapeutics (1821586) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/02/2026 3:44 PM | BIOTECHNOLOGY VALUE FUND L P (918923) Filed by MoonLake Immunotherapeutics (1821586) Subject | Form SCHEDULE 13D/A | |
| 04/02/2026 3:48 PM | BIOTECHNOLOGY VALUE FUND II LP (1102444) Reporting BIOTECHNOLOGY VALUE FUND L P (918923) Reporting Biotechnology Value Trading Fund OS LP (1660683) Reporting BVF GP HOLDINGS LLC (1803809) Reporting BVF I GP LLC (1803805) Reporting BVF II GP LLC (1803806) Reporting BVF INC/IL (1056807) Reporting BVF PARTNERS L P/IL (1055947) Reporting BVF Partners OS Ltd. (1660684) Reporting LAMPERT MARK N (1233840) Reporting MoonLake Immunotherapeutics (1821586) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 8:18 PM | BVF PARTNERS L P/IL (1055947) Reporting MoonLake Immunotherapeutics (1821586) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for MLTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/25/2026 5:12 AM | MoonLake Immunotherapeutics (1821586) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/23/2026 5:04 AM | MoonLake Immunotherapeutics (1821586) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/17/2026 2:01 PM | Cormorant Asset Management, LP (1583977) Filed by MoonLake Immunotherapeutics (1821586) Subject | Form SCHEDULE 13G | |
| 01/08/2026 7:00 AM | MoonLake Immunotherapeutics (1821586) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/22/2025 3:01 PM | MoonLake Immunotherapeutics (1821586) Issuer Santos da Silva Jorge (1920509) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/22/2025 3:02 PM | MoonLake Immunotherapeutics (1821586) Issuer Reich Kristian (1920553) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/22/2025 3:02 PM | Bodenstedt Matthias (1920545) Reporting MoonLake Immunotherapeutics (1821586) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 3:29 PM | MoonLake Immunotherapeutics (1821586) Issuer Reich Kristian (1920553) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/10/2025 3:29 PM | MoonLake Immunotherapeutics (1821586) Issuer Santos da Silva Jorge (1920509) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/08/2025 9:36 AM | MoonLake Immunotherapeutics (1821586) Subject Santos da Silva Jorge (1920509) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/08/2025 9:07 AM | MoonLake Immunotherapeutics (1821586) Subject Reich Kristian (1920553) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/14/2025 8:03 AM | Avoro Capital Advisors LLC (1633313) Filed by MoonLake Immunotherapeutics (1821586) Subject | Form SCHEDULE 13G/A | |
| 11/10/2025 4:27 PM | BIOTECHNOLOGY VALUE FUND L P (918923) Filed by MoonLake Immunotherapeutics (1821586) Subject | Form SCHEDULE 13D/A | |
| 11/05/2025 4:26 PM | MoonLake Immunotherapeutics (1821586) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/05/2025 4:25 PM | MoonLake Immunotherapeutics (1821586) Filer | Form 424B5 | |
| 11/05/2025 10:40 AM | FMR LLC (315066) Filed by MoonLake Immunotherapeutics (1821586) Subject | Form SCHEDULE 13G/A | |
| 11/05/2025 6:00 AM | MoonLake Immunotherapeutics (1821586) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/05/2025 6:02 AM | MoonLake Immunotherapeutics (1821586) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/09/2025 8:01 AM | Bodenstedt Matthias (1920545) Reporting MoonLake Immunotherapeutics (1821586) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2025 4:22 PM | Chen Bihua (1599214) Reporting Cormorant Asset Management, LP (1583977) Reporting Cormorant Global Healthcare Master Fund, LP (1618442) Reporting Cormorant Private Healthcare Fund II, LP (1747677) Reporting Cormorant Private Healthcare Fund III LP (1817320) Reporting Cormorant Private Healthcare Fund IV LP (1871297) Reporting MoonLake Immunotherapeutics (1821586) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2025 4:23 PM | Chen Bihua (1599214) Filed by MoonLake Immunotherapeutics (1821586) Subject | Form SCHEDULE 13G/A | |
| 09/29/2025 6:15 AM | MoonLake Immunotherapeutics (1821586) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/04/2025 3:01 PM | MoonLake Immunotherapeutics (1821586) Issuer Reich Kristian (1920553) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/14/2025 5:57 AM | Avoro Capital Advisors LLC (1633313) Filed by MoonLake Immunotherapeutics (1821586) Subject | Form SCHEDULE 13G | |
| 08/05/2025 6:01 AM | MoonLake Immunotherapeutics (1821586) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/05/2025 6:04 AM | MoonLake Immunotherapeutics (1821586) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/03/2025 12:23 PM | MoonLake Immunotherapeutics (1821586) Subject Moukheibir Catherine (1772130) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/09/2025 6:16 PM | BIOTECHNOLOGY VALUE FUND II LP (1102444) Reporting BIOTECHNOLOGY VALUE FUND L P (918923) Reporting Biotechnology Value Trading Fund OS LP (1660683) Reporting BVF GP HOLDINGS LLC (1803809) Reporting BVF I GP LLC (1803805) Reporting BVF II GP LLC (1803806) Reporting BVF INC/IL (1056807) Reporting BVF PARTNERS L P/IL (1055947) Reporting BVF Partners OS Ltd. (1660684) Reporting LAMPERT MARK N (1233840) Reporting MoonLake Immunotherapeutics (1821586) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2025 8:05 AM | MoonLake Immunotherapeutics (1821586) Issuer Phillips Andrew John (1921956) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2025 8:06 AM | MoonLake Immunotherapeutics (1821586) Issuer Moukheibir Catherine (1772130) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
|
| 06/09/2025 8:07 AM | MoonLake Immunotherapeutics (1821586) Issuer Xavier Ramnik (1920780) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2025 8:07 AM | Loy Spike (1920549) Reporting MoonLake Immunotherapeutics (1821586) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2025 8:08 AM | MoonLake Immunotherapeutics (1821586) Issuer Sturge Simon (1920785) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/06/2025 3:30 PM | MoonLake Immunotherapeutics (1821586) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/14/2025 9:45 AM | MoonLake Immunotherapeutics (1821586) Subject PRICE T ROWE ASSOCIATES INC /MD/ (80255) Filed by | Form SCHEDULE 13G/A | |